Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Harrison

Showing results (431-440 of 583) with videos related to

Pageof 59
Sort By:
Thorax|February 26, 2017
The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPDC Echevarria, J Steer, K Heslop-Marshall, et al.
Experimental Hematology & Oncology|September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosisMary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
Plos One|June 5, 2024
Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney diseaseJohn J Sim, Yu-Hsiang Shu, Simran K Bhandari, et al.
Cells|August 21, 2019
The Combination of IFN β and TNF Induces an Antiviral and Immunoregulatory Program via Non-Canonical Pathways Involving STAT2 and IRF9Mélissa K Mariani, Pouria Dasmeh, Audray Fortin, et al.
Journal of the American Heart Association|February 8, 2025
Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk PredictionHui Zhou, Yiyi Zhang, Matt M Zhou, et al.
Leukemia|March 2, 2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Physical Review Letters|May 23, 2006
Irreversible dynamics of the phase boundary in U(Ru0.96Rh0.04)2Si2 and implications for orderingA V Silhanek, M Jaime, N Harrison, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2009
Observation of a multiferroic critical end pointJae Wook Kim, S Y Haam, Y S Oh, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2020
Sociopolitical stress and acute cardiovascular disease hospitalizations around the 2016 presidential electionMatthew T Mefford, Murray A Mittleman, Bonnie H Li, et al.
Leukemia|May 24, 2016
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Pageof 59

Showing results (431-440 of 583) with videos related to

Sort By:
Pageof 59
Thorax|February 26, 2017
The PEARL score predicts 90-day readmission or death after hospitalisation for acute exacerbation of COPDC Echevarria, J Steer, K Heslop-Marshall, et al.
Experimental Hematology & Oncology|September 18, 2015
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosisMary Frances McMullin, Claire N Harrison, Dietger Niederwieser, et al.
Plos One|June 5, 2024
Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney diseaseJohn J Sim, Yu-Hsiang Shu, Simran K Bhandari, et al.
Cells|August 21, 2019
The Combination of IFN β and TNF Induces an Antiviral and Immunoregulatory Program via Non-Canonical Pathways Involving STAT2 and IRF9Mélissa K Mariani, Pouria Dasmeh, Audray Fortin, et al.
Journal of the American Heart Association|February 8, 2025
Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk PredictionHui Zhou, Yiyi Zhang, Matt M Zhou, et al.
Leukemia|March 2, 2017
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Physical Review Letters|May 23, 2006
Irreversible dynamics of the phase boundary in U(Ru0.96Rh0.04)2Si2 and implications for orderingA V Silhanek, M Jaime, N Harrison, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 2009
Observation of a multiferroic critical end pointJae Wook Kim, S Y Haam, Y S Oh, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 13, 2020
Sociopolitical stress and acute cardiovascular disease hospitalizations around the 2016 presidential electionMatthew T Mefford, Murray A Mittleman, Bonnie H Li, et al.
Leukemia|May 24, 2016
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosisC N Harrison, A M Vannucchi, J-J Kiladjian, et al.
Pageof 59